Navigating Tecentriq Prior Authorization for Endocrinology

The Intersection of Tecentriq and Endocrinology PA Workflows

Tecentriq, a PD-L1 inhibitor, is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans due to its use in various oncology indications. While not a primary endocrinology treatment, its administration can lead to immune-related endocrine adverse events (irAEs) such as thyroid dysfunction, hypophysitis, or diabetes. When endocrinologists manage these irAEs, the patient's record includes Tecentriq, creating a co-management scenario that necessitates precise PA coordination.

Typical Prior Authorization in Endocrinology

Endocrinology practices commonly encounter high-volume prior authorizations for medications like GLP-1 agonists (e.g., Ozempic, Mounjaro), SGLT2 inhibitors, and devices such as Continuous Glucose Monitors (CGMs) and insulin pumps. These PAs are governed by guidelines from bodies like the ADA Standards of Care and AACE Clinical Practice Guidelines, with criteria varying significantly by payer and indication. Klivira's platform is built to handle the complexity and volume inherent in these common endocrinology PA categories.

Documentation Considerations for Endocrinology-Related irAEs

• Documentation of the primary Tecentriq treatment regimen (typically managed by oncology PA).
• Evidence of endocrine-related adverse events, including relevant lab results (e.g., thyroid function, glucose levels, pituitary hormones).
• Clinical notes detailing endocrinology consultation, diagnosis of irAEs, and the proposed management plan.
• Prior authorization requests for specific endocrine medications or devices prescribed to manage irAEs (e.g., thyroid hormone replacement, insulin, or specific diabetes management tools).
• Adherence to payer-specific criteria for managing immunotherapy-induced conditions, which may require specific codes or narratives.

Klivira's Role in Complex Co-Managed PA Workflows

Klivira's platform provides a robust solution for managing prior authorizations across specialties, including complex co-management scenarios involving drugs like Tecentriq. By integrating with EMRs and payer portals, we automate data extraction, facilitate submission via compliant channels like X12 278 and ePA, and provide real-time status tracking. This ensures that critical PA data is consistent and accessible, regardless of the primary prescribing specialty.

Common Challenges in Oncology-Endocrinology PA Coordination

• Ensuring seamless coordination of PA efforts across oncology and endocrinology departments.
• Navigating variability in payer coverage for the primary oncology drug and supportive care medications for irAEs.
• Maintaining current policy libraries for both the primary drug and the evolving requirements for managing endocrine adverse events.
• Efficiently sharing comprehensive clinical documentation between disparate EMRs or departmental systems.
• Tracking the lifecycle of multiple, concurrent prior authorizations for a single patient's complex care plan.

Streamlining Endocrinology PA with Klivira

Klivira's platform is specifically designed to navigate the high volume and complexity of endocrinology prior authorizations. We leverage ADA/AACE-guideline-aware step-therapy logic for GLP-1s, manage CGM and insulin pump re-authorization workflows with adherence documentation, and track biosimilar substitution requirements per payer policy. This comprehensive approach ensures efficient processing of all endocrinology-related PAs, whether for routine diabetes management or complex irAEs.